Oxidative stress hypothesis in Alzheimer's disease: a reappraisal

Trends in Pharmacological Sciences

Volumn 29, Issue 12, 2008, Pages 609-615

  Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; 8 HYDROXYGUANINE; ACROLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BETA SECRETASE; BIOLOGICAL MARKER; CURCUMIN; DNA; FLAVONOID; GAMMA SECRETASE; ISOPROSTANE; MALONALDEHYDE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE; RNA; SELEGILINE; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BRAIN; BRAIN MITOCHONDRION; CELL DEATH; CENTRAL NERVOUS SYSTEM; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; DIET SUPPLEMENTATION; DRUG MEGADOSE; HUMAN; LIPID PEROXIDATION; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; HUMANS; NERVE DEGENERATION; OXIDATIVE STRESS; VITAMIN E;

EID: 56349145099     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.09.001     Document Type: Review

References (64)

1. Selkoe D.J. Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr. Rev. 65 Suppl. 64 (2007) S239-S243
2. Praticò D., and Sung S. Lipid peroxidation and oxidative imbalance: early functional event in Alzheimer's disease. J. Alzheimers Dis. 6 (2004) 171-175
3. Praticò D. In vivo measurements of oxidative stress. Lipids 136 Suppl. 36 (2000) S45-S47
4. Reddy P.H., and Beal M.F. Amyloid β, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14 (2008) 45-53
5. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
6. Butterfield D.A. β-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 10 (1997) 495-506
7. Smith M.A., et al. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 139-144
8. Lovell M.A., et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 (1995) 1594-1601
9. Subbarao K.V., et al. Autopsy samples of Alzheimer's cortex show increased peroxidation in vivo. J. Neurochem. 55 (1990) 342-345
10. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9 (1999) 133-146
11. Lauderdack C.M., et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J. Neurochem. 78 (2001) 413-416
12. 2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44 (1998) 410-413
13. 2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation in vivo. FASEB J. 12 (1998) 1777-1783
14. Praticò D., et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. Neurol. 59 (2002) 972-976
15. Keller J.N., et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64 (2005) 1152-1156
16. Markesbery W.R., et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 58 (2005) 730-735
17. Smith C.D., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10540-10543
18. Hensley K., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 (1995) 2146-2156
19. Smith M.A., et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9866-9868
20. Butterfield D.A., et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 22 (2006) 223-232
21. Butterfield D.A., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 1148 (2007) 243-248
22. Sultana R., et al. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J. Cell. Mol. Med. 11 (2007) 839-851
23. Mecocci P., et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36 (1994) 747-751
24. Wang J., et al. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem. 96 (2006) 825-832
25. Nunomura A., et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
26. Ding Q., et al. Ribosome dysfunction is an early event in Alzheimer's disease. J. Neurosci. 25 (2005) 9171-9175
27. Smith M.A., et al. Amyloid-β deposition in Alzheimer' transgenic mice is associated with oxidative stress. J. Neurochem. 70 (1998) 2212-2215
28. Praticò D., et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21 (2001) 4183-4187
29. Feng Z., et al. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 40 (2006) 101-109
30. Apelt J., et al. Aging-related increase in oxidative stress correlates with developmental pattern of β-secretase activity and β-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int. J. Dev. Neurosci. 22 (2004) 475-484
31. Matsuoka Y., et al. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104 (2001) 609-613
32. P264L/P264L double knock-in mouse model of Alzheimer's disease. Am. J. Pathol. 168 (2006) 1608-1618
33. 2 and kainic acid: implications for Alzheimer's disease. J. Neurochem. 96 (2006) 1322-1335
34. Karuppagounder S.S., et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology n Alzheimer's mouse model. Neurobiol. Aging (2008). www.sciencedirect.com 10.1016/j.neurobiolaging.2007.12.013
35. Schuessel K., et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis. 18 (2005) 89-99
36. Bayer T.A., et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14187-14192
37. Praticó D., et al. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16 (2002) 1138-1140
38. Resende R., et al. Brain oxidative stress in a triple transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 44 (2008) 2051-2057
39. Li F., et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89 (2004) 1308-1312
40. Nishida Y., et al. Deletion of vitamin E enhances phenotype of Alzheimer disease mouse model. Biochem. Biophys. Res. Commun. 350 (2006) 530-536
41. 2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25 (2005) 10180-10187
42. Shineman D.W., et al. Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J. Neurosci. 28 (2008) 4785-4794
43. Lim G.P., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer' transgenic mouse. J. Neurosci. 21 (2001) 8370-8377
44. Sung S., et al. Early vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimers' disease. FASEB J. 18 (2004) 323-325
45. Conte V., et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 90 (2004) 758-764
46. Matsubara E., et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 85 (2003) 1101-1108
47. Mendelsohn A.B., et al. Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort. Am. J. Epidemiol. 148 (1998) 38-44
48. Perkins A.J., et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 150 (1999) 37-44
49. Masaki K.H., et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54 (2000) 1265-1272
50. Morris M.C., et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287 (2002) 3230-3237
51. Grodstein F., et al. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am. J. Clin. Nutr. 77 (2003) 975-984
52. Engelhart M.J., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287 (2002) 3223-3229
53. Maxwell C.J., et al. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement. Geriatr. Cogn. Disord. 20 (2005) 45-51
54. Morris M.C., et al. Vitamin E and cognitive decline in older persons. Arch. Neurol. 59 (2002) 1125-1132
55. Luchsinger J.A., et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 60 (2003) 203-208
56. Zandi P.P., et al. Reduced risk of Alzheimer disease in users of antioxidants vitamin supplements: The Cache County Study. Arch. Neurol. 61 (2004) 82-88
57. Laurin D., et al. Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am. J. Epidemiol. 159 (2004) 959-967
58. Fillenbaum G.G., et al. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann. Pharmacother. 39 (2005) 2009-2014
59. Gray S.L., et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J. Am. Geriatr. Soc. 56 (2008) 291-295
60. Sano M., et al. A controlled trial of seligiline, α-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336 (1997) 1216-1222
61. Petersen R.C., et al. Vitamin E and donezepil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (2005) 2379-2388
62. Jack Jr. C.R., et al. Longitudinal MRI findings from the vitamin E and donezepil treatment study for MCI. Neurobiol. Aging 29 (2007) 1285-1295
63. Yaffe K., et al. Impact of antioxidants, zinc, and copper on cognition in the elderly. Neurology 63 (2004) 1705-1707
64. Kang J.H., et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch. Intern. Med. 166 (2006) 2462-2468